2 Marijuana Stocks To Watch For Gains Next Week

2 Marijuana Stocks To Watch For Gains Next Week

2 Marijuana Stocks To Watch For Gains Next Week | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Fri, 15 Jan 2021 20:17:45 +0000

2 Marijuana Stocks To Watch In 2021 That May See More Gains

2 Marijuana Stocks To Watch In 2021 That May See More Gains

2 Marijuana Stocks To Watch In 2021 That May See More Gains | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Thu, 14 Jan 2021 18:58:38 +0000

Are You Adding These Marijuana Stocks To Your 2021 Watchlist?

Are You Adding These Marijuana Stocks To Your 2021 Watchlist?

Are You Adding These Marijuana Stocks To Your 2021 Watchlist? | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Thu, 14 Jan 2021 20:15:58 +0000

Are You Adding These Marijuana Stocks To Your 2021 Watchlist?

Are You Adding These Marijuana Stocks To Your 2021 Watchlist?

Are You Adding These Marijuana Stocks To Your 2021 Watchlist? | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™

Published at Thu, 14 Jan 2021 20:15:58 +0000

Truss CBD USA, a Molson Coors and HEXO Corp Joint Venture, Launches Veryvell™ Sparkling CBD Water in Colorado

Truss CBD USA, a Molson Coors and HEXO Corp Joint Venture, Launches Veryvell™ Sparkling CBD Water in Colorado

Truss CBD USA, a joint venture majority owned by Molson Coors Beverage Company (“Molson Coors”) and operated in partnership with HEXO Corp, today announces the U.S. launch of Veryvell, a new line of non-alcoholic, sparkling CBD beverages, exclusively available in Colorado.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005291/en/

Veryvell is a hemp-derived, adaptogenic, sparkling CBD water infused with a crisp taste, zero calories and zero sugar. Veryvell is now available to Colorado-based consumers both online and at select retailers in Colorado in three flavors: Focus (Grapefruit Tarragon), Mind & Body (Strawberry Hibiscus) and Unwind (Blueberry Lavender).

“Last year, we redefined ourselves as Molson Coors Beverage Company and in doing so, laid out a clear vision of leveraging the competitive strengths of our storied foundation in beer to grow in new spaces beyond the beer aisle,” said Pete Marino, president of the emerging growth division for Molson Coors. “Truss’ entry into the CBD market in Colorado and the launch of Veryvell, a brand we believe will resonate well with Colorado consumers, is another example of Molson Coors’ expansion into new beverage categories.”

Veryvell marks Truss CBD USA’s first entry in the American CBD market and is another example of Molson Coors’ moves to cultivate the company’s beverage offerings. The diversification of the Molson Coors portfolio includes an exclusive agreement with The Coca Cola Company to manufacture, market, and distribute Topo Chico Hard Seltzer in the U.S. as well as an expanding roster of non-alcoholic innovations. This includes an investment in ZENWTR, created by noted beverage entrepreneur Lance Collins, a distribution agreement with La Colombe for their RTD line of canned coffees, and a recently announced North American distribution partnership with ZOA, a new energy drink being launched by a multi-faceted team of fitness, health and beverage industry changemakers including Dwayne “The Rock” Johnson.

“Whether you’ve dabbled in CBD before or are curious to try something new, Veryvell invites a moment of self-care to your day through a refreshing and balanced mix of hemp extracts and natural flavors,” said Jane Armstrong Hockman, Truss CBD USA general manager. “Each beverage in the product line offers a unique blend of CBD and adaptogens, giving consumers the freedom to pick the combination that best meets them in the moment. We are thrilled to bring our beverage expertise and commitment to quality to this emerging wellness category.”

Crafted and exclusively available in Colorado, Veryvell comes in three distinct varieties, each infused with 20mg of hemp-derived, non-psychoactive CBD and adaptogens:

  • Focus, a combination of grapefruit and tarragon with ginseng and guarana
  • Mind & Body, a blend of strawberry and hibiscus with ashwagandha and elderberry
  • Unwind, a mix of blueberry and lavender with ashwagandha and L-Theanine

Veryvell is now available for purchase by Colorado-based consumers at www.trusscbdusa.com and on shelves at select Colorado retail stores in a variety of SKUs including individual 12 oz cans, four-packs as well as online-exclusive eight-packs and 12-pack variety packs. Suggested retail price for a 12 oz can of Veryvell is $3.99 and $14.99 for a four-pack.

Veryvell is produced and distributed within Colorado state lines following the state’s established regulatory framework for hemp-derived CBD in food and beverages and is exclusively distributed by Coors Distributing Company. Truss CBD USA is distinct from Truss Beverages, Molson Coors and HEXO’s joint venture in Canada that focuses on non-alcoholic, cannabis-infused beverages.

For those Colorado-based consumers interested in learning more about Veryvell, please visit www.trusscbdusa.com or @liveveryvell on Facebook and Instagram.


Truss CBD USA is a joint venture between Molson Coors Beverage Company and HEXO Corp designed to explore opportunities for non-alcoholic, hemp-derived CBD exclusively in the United States. With all production and distribution concentrated within states that permit such products, the Truss CBD USA portfolio focuses on hemp-driven, CBD beverages that span a range of flavor profiles and drinking occasions, starting with the launch of Veryvell sparkling CBD water. For those Colorado-based consumers interested in learning more, visit www.trusscbdusa.com or @LiveVeryvell on Facebook and Instagram.


For over two centuries Molson Coors has been brewing beverages that unite people for all of life’s moments. From Coors Light, Miller Lite, Molson Canadian, Carling, and Staropramen to Coors Banquet, Blue Moon Belgian White, Blue Moon LightSky, Vizzy, Leinenkugel’s Summer Shandy, Creemore Springs and more, Molson Coors produces some of the most beloved and iconic beer brands ever made. While the company’s history is rooted in beer, Molson Coors offers a modern portfolio that expands beyond the beer aisle as well.

The company’s commitment to raising industry standards and leaving a positive imprint on our employees, consumers, communities and the environment is reflected in Our Imprint and our 2025 sustainability targets. To learn more about Molson Coors Beverage Company, visit molsoncoors.com, MolsonCoorsOurImprint.com or on Twitter through @MolsonCoors.


HEXO Corp is an award-winning consumer packaged goods cannabis company that creates and distributes innovative products to serve the global cannabis market. Incorporated in 2013 under the name The Hydropothecary Corporation, the company was created to meet the needs of the Canadian medical cannabis market. With the advent of Canada’s legalized market in 2018, the company became HEXO Corp, serving both the adult-use (recreational) and Canadian medical markets through its house of brands. Today, HEXO legally operates out of three cutting edge facilities for genetics, cultivation and manufacturing. Under the company’s Powered by HEXO TM business strategy, Hexo Corp partners with established CPG companies to provide cannabinoid isolation technology, licensed infrastructure and regulatory expertise. HEXO is dual listed on the Toronto Stock Exchange and New York Stock Exchange under ticker symbol “HEXO.”


Adam Scholder
ICF Next
(847) 204-0949


Share - Facebook

Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Wed, 13 Jan 2021 13:56:19 +0000

Gateway Proven Strategies Announces Cannabis License Procurement Services for 5 New Legalized States

Gateway Proven Strategies Announces Cannabis License Procurement Services for 5 New Legalized States

Cannabis genetics are the cornerstone of Green Dot Labs’ Boulder, Colo.-based concentrates operation, and according to co-founder Dave Malone, the craft beer industry provided the inspiration he needed to give the company’s unique cultivars their own identities.

Malone says the craft brewing industry started out as a select few companies with lines of beers that were almost indistinguishable among consumers, but as soon as brands began investing in marketing, consumers started gravitating toward specific brands.

The cannabis industry, he says, has a lot to learn from this approach.

“That’s what we’re aiming to do with our genetics, is give them their own identity,” Malone says. “People may prefer different brands for whatever reason, but they still look at our Cherry Fluff strain, for instance, which is [branded as] a beautiful cherry on a big pile of whipped cream, and [the marketing is] very captivating and seductive. People identify with that.”

Photo courtesy of Green Dot Labs

Green Dot Labs’ Peach Brain Freeze cultivar

Dan Banks, director of cultivation strategy for Denver- based Lightshade, echoes this sentiment, adding that marketing is beginning to play a large role in the cannabis genetics space, with name-brand recognition starting to emerge among consumers.

“You have a couple different demographics,” Banks says. “You have people who are used to getting certain things from dispensaries, [and] they want to see those things maintained. Then you have people who are interested in anything new and checking that out, and if it’s new, then they’re like, ‘I want more of that’ or ‘I want more from that lineage.’”

Founded in 2011, Lightshade is one of the largest Colorado-owned, vertically integrated cannabis operators in the state. The company operates a greenhouse operation in Denver, as well as four indoor grow facilities.

When Banks joined Lightshade in late 2019, the company was cultivating roughly a dozen varieties across its five facilities, but it has since grown its genetics library to nearly 70 cultivars, with roughly 30 in regular production.

“Over the last year and some change, we’ve grown the library of genetics in the company and then implemented what we call a phenotyping program,” Banks says. “Basically, that’s a systematic way of introducing new varieties into production and gathering information about their performance, both on the horticultural side and also on the quality [and] potency side, as well.”

Lightshade acquired vertically integrated cannabis operator Sacred Seed last summer, which provided the company with a large bank of new genetics. Heading into 2021, Lightshade will establish an in-house breeding program to produce unique and proprietary varieties.

“[We’re] really trying to get some unique variety, … while also trying to cater to consumers that are looking for specific name-brand strains, as well,” Banks says, adding, “A lot of the things that people are excited about right now, there’s a lot of marketing behind that. Sometimes that marketing has a lot of substance backing it up, and other times it’s just a lot of hype.”

Photo courtesy of Lightshade

Lightshade plans to establish an in-house breeding program this year to produce unique and proprietary cannabis varieties.

Along those same lines, Malone says that companies can invest in robust marketing for a mediocre product, but that product still won’t do as well as better-quality offerings—product quality and marketing must go hand in hand.

“You can put all of the branding in the world on a jar of undifferentiated product and it won’t do well, but if you have integrity from the core, which is your genetics, it really extrapolates the value downstream when you do add these marketing layers to the product,” he says.

Green Dot Labs is entering its seventh year and maintains an in-house breeding program to create genetics specifically for its extracts.

“A lot of cannabis companies are curating genetics through a vast network that are available worldwide, whereas we’ve taken that into our own hands and steered the ship toward the goals that we set out, [so we’re] not necessarily … at the mercy of the market to provide content for the brand,” Malone says.

As it breeds new strains, Green Dot Labs brands them, which Malone says has become especially important in recent years as consumers have started to expect more from cannabis extracts.

“The consumer wants to know more,” he says. “They want to know the heritage, the lineage, where the strain came from, [and] what kind of flavors and experience they can expect when they open the package.”

Green Dot Labs has roughly 20 branded strains in its genetics library, and Malone says the branded cultivars outsell the company’s non-branded offerings, 3-to-1.

“There is so much content out there for the average consumer,” he says. “It’s overwhelming to find what strains work best for you. Everything in the current market, specifically here in Colorado, is extremely generic. A lot of companies haven’t taken this extra measure to differentiate their genetic portfolios.”

It’s a cultivator’s responsibility to tell the consumer why his or her product is better than others through branding, Malone says. The main points of brand differentiation, he adds, will be proprietary genetics that offer unique flavors and experiences, as well as the quality and efficiency with which these cultivars are produced.

Creating a Differentiated Experience

When Green Dot Labs launched its breeding program, Malone says it took a qualitative approach. The company pursued genetics that mirrored nearly every type of fruit, from a banana to an apple, and also started breeding what he calls “gassy” varieties. Since not all genetics are created equal when it comes to performing well in the extraction process, data collected during extraction helped the Green Dot Labs team further refine its genetics offerings. Specifically, the company looked at extract yields, and pursued cultivars with differentiated flavors that offered as much resin as possible.

Green Dot Labs recently closed on a new facility in Colorado that will allow the company to expand and increase its R&D capacity as it heads into the new year.

“We’re going to be delivering new strains and new flavors that have never even been imagined by the most sophisticated cannabis connoisseur,” Malone says. “That’s the goal now.”

Another one of the company’s goals, he adds, is to find strains that perform well during solventless extraction.

Photo courtesy of Green Dot Labs

Green Dot Labs will expand its extracts line this year by improving the resin structure of its favorite plants while also creating new cultivars.

“You see a lot of connoisseurs wanting to enjoy the solventless extract, but the problem with this and why it’s so expensive is because your yields are highly unpredictable and heavily predicated on the quality of the plants you produce and the genetics,” Malone says, adding that Green Dot Labs currently has 10 cultivars in its genetics library that work well with solventless extraction.

As the company heads into 2021, it will expand its extracts line by improving the resin structure of its favorite plants while also creating new cultivars.

“We like to offer something for everyone,” Malone says. “Each consumer has a certain taste, and we don’t want to alienate anybody. We want to make it so anybody who likes cannabis can come to Green Dot Labs and this can be their one-stop shop.”

For Banks and the Lightshade team, 2021 will be focused on establishing the company’s breeding program, which will include sourcing more genetic material and identifying desirable plants to work with.

“What we’ll do is try to establish a bank of male plants that we can then use to start crossing with females, and the other thing that we’ll do is look at partnering with some of the companies that are offering genetic mapping in order to get a better understanding of the source genetics that we have,” Banks says. “You bring something in and it has a name, but is it what they’re saying it is? We don’t know, but we can look into that.”

The market continues to change rapidly as consumers gain a better understanding of terpene profiles and minor cannabinoids, adds Nick Drury, Lightshade’s director of cultivation operations, and Lightshade will lean into consumer education and marketing to address these topics.

“People are realizing that it’s not just about THC content,” Drury says. “It’s also about your overall terpene profile, and how those terpenes and cannabinoids are interacting to produce a high. As people start to increase their own education into certain things, I think what you’ll start to see in the market as a whole is a shift … in terms of what people are looking for, and a little bit more interest in specific profiles, [which will do] away with the indica/sativa/hybrid terminology. … That will open up the market to a lot of cultivars that may be low in overall THC, but they might be high in CBN and all these other cannabinoids and all the different terpene profiles. … I would say education and marketing are huge in the upcoming year.”

“I think branding is just going to become more important than ever,” Malone adds. “[With] the quality [and] the differentiation being so vast, how you present the product to the consumer is really where the rubber is going to hit the road once competition elevates to this level.”

Published at Wed, 13 Jan 2021 17:28:00 +0000

New York Governor Calls For Marijuana Legalization In State Of The State Address

New York Governor Calls For Marijuana Legalization In State Of The State Address

New York Gov. Andrew Cuomo (D) on Monday again discussed the need to legalize marijuana in 2021.

During a State of the State address, the governor said enacting the reform will help fill a significant budget deficit and promote restorative justice. The stepped up push comes days after he unveiled initial details of his administration’s latest legalization proposal.

“We will legalize adult-use recreational cannabis, joining 15 other states who’ve already done so,” Cuomo said in the speech. “This will raise revenue and will end the over-criminalization of this product that has left so many communities of color over-policed and over-incarcerated.”

Read More

Published at Tue, 12 Jan 2021 16:16:46 +0000

New York Medical Cannabis Industry Association Announces New Executive Board

New York Medical Cannabis Industry Association Announces New Executive Board

New York, January 8, 2021 – PRESS RELEASE – In anticipation of a busy and productive state legislative session in Albany, the New York Medical Cannabis Industry Association (NYMCIA) is announcing new members of its leadership team who will play key roles in the upcoming cannabis legalization debate.

Aquila Powell, Senior Director of Government Affairs for Acreage Holdings; Marcia Maxwell, Eastern Regional Director of Government Affiars for Cresco Labs; Dina Rollman, SVP, Government & Regulatory Affairs at Green Thumb Industries; and Jeremy Unruh, SVP for Public and Regulatory Affairs at Pharmacann are part of NYMCIA’s expanded executive board, which now includes the following:

  • President, Ngiste Abebe, Director of Public Policy at Columbia Care
  • Chair, Marcia Maxwell, Eastern Regional Director of Government Affairs at Cresco Labs
  • Vice Chair, Matt Harrell, Vice President of Government Affairs for Curaleaf
  • Vice President, Aquila Powell, Senior Director of Government Affairs for Acreage Holdings
  • Vice President, Dina Rollman, Senior Vice President of Government and Regulatory Affairs at Green Thumb Industries
  • Treasurer, Barrington Rutherford, Senior Vice President of Real Estate and Community Integration for Cresco Labs
  • Secretary, Jeremy Unruh, Senior Vice President for Public and Regulatory Affairs at Pharmacann

The association was created in 2016 to protect the interests of patients and advocate for easier and more affordable access to medical cannabis across New York, which has one of the most restrictive programs of its kind in the nation.

NYMCIA has also long championed a fair, equitable and accessible adult-use cannabis program that addresses the longstanding and disproportionate harm inflicted on minority and low-income communities by the failed war on drugs.

The association’s newly formed executive board stands ready to participate in a robust debate in the coming months aiming to establish a safe and well-regulated adult-use program that creates jobs and generates much-needed revenue for New York as it recovers from the pandemic-induced economic downturn. 

“The Association is confident that by the close of this session, New York will join neighboring states by passing a comprehensive adult-use bill that solidifies its role as a national progressive leader,” said Abebe. “The medical cannabis industry has already demonstrated across the U.S. that it can help seed equity efforts while quickly ramping up an adult-use program, and we are prepared to do the same in New York – if given the chance.”

“It is well past time for New York to harness the untapped potential of the cannabis industry to create good-paying jobs and new revenue in the face of significant financial challenges,” added Maxwell. “This is the year we must put our differences aside and create a robust, inclusive adult-use program that prioritizes economic growth, social equity, public safety, and reinvestment into disadvantaged communities that have long suffered from the War of Drugs.”

The governor has repeatedly indicated that adult-use legalization will be among his top priorities this year. NYMCIA believes New York should follow the lead of states around the nation and allow both medical and adult-use cannabis to merge under one roof, as well as the sale of full flower to assure a strong and successful program.

To learn more visit https://www.protectnymedmar.com/.

Published at Mon, 11 Jan 2021 18:48:00 +0000

ATAI or MindMed: Which Is The Better Opportunity?

ATAI or MindMed: Which Is The Better Opportunity?

Last week, Psychedelic Stock Watch published our latest look at the ATAI Life Sciences IPO, including speculation that the new listing could come as early as the end of January. As we noted, this means that investors need to quickly decide upon their strategy re: investing in ATAI.

In formulating that strategy, perhaps the first question that investors will address is: ATAI or MindMed?

Comparing the industry leaders

ATAI has the largest, most-diversified business model in the psychedelics space. It has a total of nine research partnerships in place with different corporate partners, including its flagship investment (>20%) in Compass Pathways (US:CMPS).

MindMed Inc (CAN:MMED / US:MMEDF / GER:MMQ) is the closest parallel to ATAI. Via its research partnership with the University of Basel (Switzerland), MindMed has the deepest portfolio of drug R&D initiatives that are already into formal clinical trials.

Purely from an operations perspective, any serious investor in psychedelic stocks would like to hold positions in both companies. Currently, these are simply the two psychedelics companies with the most meat-on-the-bone for investors.

But markets don’t work like that. Investors also need to factor in the cost of taking a position in one or both companies. In other words, it becomes an exercise in cost/benefit analysis.

For investors who bought in early with MindMed as a public company or who participated in one of ATAI’s previous financing rounds, this isn’t an issue. For everyone else, price is a critical factor in reaching their decision.

Currently, MindMed sits with a market cap above US$1 billion. ATAI is expected to be priced between $1 – $2 billion. Not much to choose between the two companies if those numbers remain the same by the time ATAI has its IPO.

Which is the better opportunity for investors (at that price)?

Part of the answer to this question is dependent on an investor’s risk profile.

Less risk with ATAI, more upside with MindMed?

More conservative investors will likely lean toward ATAI. The best-capitalized psychedelics company. Expected to have a premier NASDAQ listing. A deep IP portfolio via its corporate partnerships. For those reasons, it will likely trade closer to fully valued, right from its IPO.

On the other hand, those with greater risk tolerance may lean toward MindMed.

MindMed doesn’t have a premier exchange listing – yet. It hasn’t raised capital quite as well as ATAI. But it’s added roughly CAD$200 million via its 2020 financings and currently sits with US$145 million in cash. A proven ability to raise lots of capital.

MindMed’s clinical R&D is at least as advanced as that of ATAI. But because it works with a single research partner (University of Basel), it may not be quite as diversified as ATAI’s partnerships.

Should investors in psychedelic stocks be holding both companies?

That’s a likely strategy for more conservative investors who are looking to focus their holdings on only a couple of companies. Broad exposure to the sector while minimizing risk.

For other investors, whether or not to hold both companies will depend upon their own Big Picture view of the industry.

Some investors see the psychedelic drug industry as primarily a drug development story. A Mental Health Crisis is raging across that already affects over 1 billion people.

The current standard of care is grossly deficient for most of these mental health conditions. Meanwhile, clinical trials with psychedelics-based therapies have been yielding spectacular results.

Numerous multi-billion-dollar drug markets are potentially on the table.

Investors primarily focused on the home-run potential of drug development may feel compelled to hold both stocks.

Conversely, other investors see the psychedelic drug industry more in terms of a drug treatment story. Nearly all psychedelic drugs currently in clinical studies are being integrated with some form of psychotherapy.

Consequently, when it comes to revenue streams, many investors are more tuned-in to the services/treatment side of this industry. In the United States alone, total revenues for mental health services are currently ~$300 billion per year.

Investors wanting a strong portfolio emphasis on psychedelics-assisted clinics and ancillary services may only have room in their portfolio for one industry leader or the other.

Then they can augment that with holdings in some of the psychedelics companies that have already staked out a stronger position on the treatment side of the industry. Companies like Field Trip Health (CAN:FTRP / US:FTRPF), Numinus Wellness (CAN:NUMI / US:LKYSF) or Mind Cure Health (CAN:MCUR / US:MCURF).

Industry leaders are especially attractive to investors in emerging industries. These are companies that generally offer:

  • Greater visibility
  • More liquidity
  • Deeper operations
  • Better capitalization

For all those reasons, such companies generally represent lower risk propositions than smaller peers.

ATAI Life Sciences and MindMed Inc have already attracted strong investor following for good reasons. Each offers multiple investment drivers in a very well-capitalized business model.

It would be difficult for any serious investor in psychedelics to turn their back on both companies. With many similarities, which of the two companies is the better value may largely come down to the price at which investors can gain entry.

DISCLOSURE: The writer holds shares in MindMed Inc, Numinus Wellness and MindCure Health. Mind Cure Health is a client of Psychedelic Stock Watch.

Published at Tue, 12 Jan 2021 06:00:07 +0000

Investing In The Green Rush